Showing results (41-50 of 55) with videos related to
Sort By:
Pageof 6
Medrxiv : the Preprint Server for Health Sciences|March 3, 2023
New tuberculosis vaccines in India: Modelling the potential health and economic impacts of adolescent/adult vaccination with M72/AS01 <sub>E</sub> and BCG-revaccinationRebecca A Clark, Chathika K Weerasuriya, Allison Portnoy, et al.Vaccine|September 9, 2015
The estimated impact of natural immunity on the effectiveness of human papillomavirus vaccinationSuzette M Matthijsse, Jan A C Hontelez, Steffie K Naber, et al.Plos Medicine|February 12, 2026
Estimating the population impact of new tuberculosis vaccines depending on efficacy against infectious asymptomatic tuberculosis: A modelling studyHira Tanvir, Rebecca A Clark, Tom Sumner, et al.BMC Medicine|August 4, 2023
New tuberculosis vaccines in India: modelling the potential health and economic impacts of adolescent/adult vaccination with M72/AS01<sub>E</sub> and BCG-revaccinationRebecca A Clark, Chathika K Weerasuriya, Allison Portnoy, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|December 17, 2004
Can population differences explain the contrasting results of the Mwanza, Rakai, and Masaka HIV/sexually transmitted disease intervention trials?: A modeling studyRichard G White, Kate K Orroth, Eline L Korenromp, et al.Plos One|September 5, 2018
The health impact of human papillomavirus vaccination in the situation of primary human papillomavirus screening: A mathematical modeling studySuzette M Matthijsse, Steffie K Naber, Jan A C Hontelez, et al.Plos Medicine|February 20, 2026
The potential impact of reduced international donor funding on the household economic burden of tuberculosis in low- and middle-income countries: A modeling studyAllison Portnoy, Rebecca A Clark, Mark Jit, et al.Plos Neglected Tropical Diseases|January 20, 2017
The Socioeconomic Benefit to Individuals of Achieving the 2020 Targets for Five Preventive Chemotherapy Neglected Tropical DiseasesWilliam K Redekop, Edeltraud J Lenk, Marianne Luyendijk, et al.Plos Medicine|January 24, 2023
The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling studyAllison Portnoy, Rebecca A Clark, Matthew Quaife, et al.The Lancet. Global Health|March 16, 2023
The impact of alternative delivery strategies for novel tuberculosis vaccines in low-income and middle-income countries: a modelling studyRebecca A Clark, Christinah Mukandavire, Allison Portnoy, et al.Pageof 6